Welcome to our dedicated page for Tff Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (TFFP) has been described in its public communications as a clinical-stage biopharmaceutical company built around its proprietary Thin Film Freezing (TFF) technology platform. Over time, the company has issued news covering its inhaled dry powder product candidates, collaborations with academic and government partners, and later, significant corporate developments related to winding down operations and delisting from Nasdaq.
Earlier news from TFF Pharmaceuticals has focused on the progress of its TFF-based pipeline. This includes updates on tacrolimus inhalation powder (TFF TAC) for the prevention of lung transplant rejection, where the company has reported Phase 2 clinical data on safety, pharmacokinetics, biomarker outcomes, and patient enrollment. Additional releases have highlighted preclinical data for TFF-formulated influenza vaccine candidates and work on inhaled or intranasal dry powder formulations designed to address respiratory viral infections, including influenza and COVID, often in collaboration with institutions such as Emory University and Cleveland Clinic and with support from U.S. government agencies.
News items have also described the broader capabilities of the Thin Film Freezing platform, including its application to vaccines, small and large molecules, and biologics, and its potential to create temperature-stable dry powders suitable for inhalation or topical delivery. Corporate updates have included financial results, regulatory interactions with the U.S. Food and Drug Administration regarding the TFF TAC program, and the engagement of advisors to explore partnership and licensing opportunities.
More recent announcements mark a shift in focus, with TFF Pharmaceuticals disclosing the termination of its employees, a decision to wind down operations, and plans for liquidation and dissolution. The company has also announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market, stating that this step is being taken in connection with the planned liquidation. This news page provides a record of both the scientific and clinical developments associated with the TFF platform and the subsequent corporate decisions affecting the company’s trading status and future.
TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will participate in a fireside chat at the 34th Annual Roth Conference held in Dana Point, California, from March 13 to 15, 2022. The chat is scheduled for March 14 at 10:30 AM PT (1:30 PM ET) and will be moderated by Jonathan Aschoff, Ph.D., from Roth Capital Partners. Management will also engage in one-on-one meetings during the event. TFF Pharmaceuticals is focused on innovative drug products utilizing its patented Thin Film Freezing technology, aimed at improving the solubility and absorption of poorly water-soluble drugs.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will release its fourth quarter 2021 financial results and business update on March 24, 2022, following the close of U.S. markets. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss financial results and recent corporate developments. Investors can join via a toll-free number or webcast, with a question-and-answer session following the presentation. The company focuses on innovative drug products using its patented Thin Film Freezing technology, enhancing the delivery of poorly water-soluble drugs.
TFF Pharmaceuticals (NASDAQ: TFFP) has announced a collaboration with Catalent to enhance the scalability and manufacturing of its proprietary Thin Film Freezing (TFF) technology. This agreement aims to develop dry powder formulations for biotherapeutics, particularly focusing on inhaled delivery systems. Catalent will utilize its expertise in dry powder development to support TFFP's technology, potentially increasing the adoption of pulmonary drug delivery. This partnership is expected to expand TFFP’s manufacturing capabilities and open opportunities for technology licensing.
TFF Pharmaceuticals (NASDAQ: TFFP) announced promising results from its inhaled niclosamide product against COVID-19 variants, Delta and Omicron. The in vitro assays revealed complete viral replication inhibition at concentrations as low as 1μM, outperforming other treatments like nirmatrelvir. A Phase 1 trial showed the 6 mg dosage is well tolerated, producing effective concentrations in lung fluid. The company anticipates delivering safety and pharmacokinetic data by the end of Q1 2022, enhancing confidence in niclosamide's therapeutic potential against COVID-19 in vulnerable populations.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the completion of enrollment in its Phase 1 clinical trial of a dry powder formulation of niclosamide, aimed at treating COVID-19 and respiratory viral diseases. The trial included 40 healthy subjects, with safety results expected by the end of Q1 2022. The Safety Management Committee has recommended a 12 mg daily dose for Phase 2 testing. Niclosamide has shown potential against SARS-CoV-2 variants, with a previous study reporting a seven-fold reduction in viral load in treated models. UNION Therapeutics holds an option for exclusive licensing of the formulation.
TFF Pharmaceuticals (TFFP) has announced the full readout of safety and pharmacokinetic data from its Phase 1b study of Inhaled Voriconazole Powder (TFF VORI) in asthma patients. The study shows TFF VORI is well tolerated, with no differences in drug absorption between asthma and healthy patients. The company plans to advance to Phase 2 trials in 2022, potentially expanding the treatment to Allergic Bronchopulmonary Aspergillosis. TFF Pharmaceuticals aims to improve efficacy and safety of IPA treatment through direct lung delivery, enhancing patient outcomes.
Summary not available.
TFF Pharmaceuticals (NASDAQ: TFFP) reported substantial progress in its clinical and corporate developments during Q3 2021, with significant advancements in its Inhaled Voriconazole and Tacrolimus programs, which are set to enter Phase 2 trials by year-end. The company also noted positive outcomes in its partnerships for antiviral programs, particularly AUG-3387 and niclosamide, with the latter's Phase 1 trial recently initiated. Financially, TFFP reported a net loss of $8.7 million, up from $5.1 million in Q3 2020, with R&D expenses increasing to $6.3 million from $2.8 million, reflecting ongoing investments in their drug development pipeline.
TFF Pharmaceuticals, Inc. announced positive results from its Phase 1b clinical trial for Voriconazole Inhalation Powder (TFF VORI), designed for the treatment of Invasive Pulmonary Aspergillosis (IPA) in asthma patients. The data indicates that TFF VORI is well tolerated, supporting the move to Phase 2 trials which may include patients with hyperreactive airway diseases. This development could also open avenues for treating Allergic Bronchopulmonary Aspergillosis (ABPA). The innovative TFF platform enhances drug delivery directly to the lungs, potentially improving efficacy and safety.
AUSTIN, Texas, Nov. 08, 2021 - TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will present a corporate overview at the 12th Annual Jefferies London Healthcare Conference from November 16-19, 2021. The presentation will be available on demand starting November 18, 2021, at 3:00 AM ET. TFF Pharmaceuticals specializes in drug products using its patented Thin Film Freezing technology, which enhances the solubility and absorption of poorly water-soluble drugs.
The replay will be accessible for 30 days post-event on the Company’s website.